An FDA peptide panel will meet this week to determine whether compounding pharmacies can legally resume producing popular wellness peptides, despite stark warnings from the agency’s own career scientists. The two-day meeting of the Pharmacy Compounding Advisory Committee starts Thursday and will review evidence for seven highly sought-after injectable compounds.
The committee’s decision could reshape the rapidly growing wellness and longevity market. Millions of Americans have turned to peptides for injury recovery, muscle growth, fat loss, and skin health. However, none of the seven compounds under review—including TB-500, BPC-157, and MOTs-C—has undergone the large-scale clinical trials required for standard FDA drug approvals.
FDA Peptide Panel Faces Pressure Over Gray Market
Peptides are strings of amino acids that act as signaling molecules in the body, performing critical functions. While some, like insulin, occur naturally, others are modified versions, similar to the blockbuster GLP-1 weight loss drugs. BPC-157, for instance, is derived from a peptide found in human stomach juices, while TB-500 is related to a molecule found in many cell types.
Compounding pharmacies traditionally make customized medications for patients with specific needs, such as allergies to mass-produced drug ingredients. Under Biden-era restrictions, these pharmacies were largely barred from producing wellness peptides due to safety concerns and a lack of efficacy data. Proponents argue this ban did not eliminate demand but simply pushed it underground, fueling a dangerous gray market of overseas suppliers. Americans are now injecting themselves with unvetted substances purchased abroad.
“When peptides were pulled from the regulated compounding pharmacies, demand didn’t go away. It went into the underground,” Gary Brecka, a wellness influencer and podcaster whose company markets peptides, told reporters during a recent briefing held by the American Academy of Peptide Medicine. “This is not a question of whether Americans will use peptides.”
RFK Jr. and the MAHA Agenda
The upcoming meeting highlights a growing tension between Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again agenda and the traditional scientific establishment. Kennedy has publicly advocated for lifting restrictions on peptides and frequently promotes their benefits as part of a broader push for alternative therapies.
In June, the FDA overhauled the advisory committee’s roster. Many new members have direct ties to the peptide industry, working for compounding pharmacies or clinics that offer the therapies. On Tuesday, the agency added a handful of temporary voting members from academic institutions, designating them as experts in specific peptides. The FDA has not commented on the reasons for these sudden changes to the panel’s composition.
Sparse Clinical Evidence vs. Real-World Use
Meanwhile, the FDA’s internal scientists are advising against allowing compounding pharmacies to produce any of the seven peptides. In an evidence review posted before the meeting, they noted that data comes primarily from preclinical animal studies and is severely limited for humans. There were no human clinical studies identified for TB-500, and another compound, Semax, showed “insufficient evidence of effectiveness.”
“I see it as very risky,” says Paul Knoepfler, a cell and molecular biologist at the University of California, Davis, who tracks peptide demand. “These are drugs and they haven’t been scientifically proven.”
Knoepfler warns that peptides, especially at incorrect doses, could inadvertently promote cancer growth or trigger dangerous immune responses. He also expressed concern over the possibility of FDA leadership overriding its own scientists. “I think that’s not good for the FDA,” he says. “I think that undermines their authority and consistency.”
Industry Pushes for Reclassification
Despite the lack of clinical trials, medical providers argue that real-world experience justifies reclassification. The FDA committee will review data for specific conditions like migraines, ulcerative colitis, opioid withdrawal, and wound healing. However, if the FDA reclassifies the peptides, clinicians would have the discretion to prescribe them off-label for a much wider range of uses.
Medical providers should be honest about the “relatively sparse clinical evidence for these peptides,” says Dr. Anant Vinjamoori, chief medical officer of Hims, which plans to offer the therapies if the FDA allows it. “At this point, we do have experience that’s accumulated across close to a decade — thousands of physicians, close to millions of patients — that seems to indicate these peptides can be beneficial to promote health.”
What Happens Next
If the FDA peptide panel votes to recommend easing restrictions, the agency will face a decision on whether to formally reclassify the compounds, allowing compounding pharmacies to resume production under regulated conditions. This could effectively dismantle the overseas gray market by providing a domestic, regulated supply chain for American consumers.
However, a decision to override the recommendations of career scientists could set a precedent for how the FDA handles future wellness trends under the current administration. Patients and providers should watch closely for the panel’s final vote on Friday, which will signal whether the agency prioritizes real-world anecdotal evidence over traditional clinical trial data. Regardless of the outcome, the demand for wellness peptides shows no sign of slowing down.
— Aisha Mensah, health desk, AXO News
— Aisha Mensah, health desk, AXO News